BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Rating Upgraded by Wall Street Zen

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently issued reports on BBOT. Stifel Nicolaus lowered their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Morgan Stanley dropped their target price on shares of BridgeBio Oncology Therapeutics to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 21st. Oppenheimer cut their target price on shares of BridgeBio Oncology Therapeutics to $16.00 and set an “outperform” rating for the company in a research note on Tuesday, October 20th. Wedbush reduced their price target on shares of BridgeBio Oncology Therapeutics to $9.00 and set an “outperform” rating for the company in a report on Wednesday, November 11th. Finally, JPMorgan Chase & Co. reduced their price target on shares of BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, September 11th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Check Out Our Latest Report on BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics Price Performance

BBOT opened at $2.14 on Friday. The firm has a market capitalization of $171.74 million, a P/E ratio of -0.99 and a beta of 0.86. The stock’s 50 day moving average price is $3.65 and its two-hundred day moving average price is $7.68. BridgeBio Oncology Therapeutics has a 12-month low of $1.98 and a 12-month high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.22. As a group, analysts anticipate that BridgeBio Oncology Therapeutics will post -2.75 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Large investors have recently added to or reduced their stakes in the company. Regents of The University of California bought a new stake in shares of BridgeBio Oncology Therapeutics during the third quarter valued at approximately $10,289,000. Opaleye Management Inc. raised its stake in shares of BridgeBio Oncology Therapeutics by 1,213.8% in the second quarter. Opaleye Management Inc. now owns 700,000 shares of the company’s stock valued at $5,334,000 after purchasing an additional 646,718 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of BridgeBio Oncology Therapeutics in the third quarter valued at $1,980,000. Granahan Investment Management LLC acquired a new position in shares of BridgeBio Oncology Therapeutics in the first quarter valued at $2,068,000. Finally, Avidity Partners Management LP bought a new position in BridgeBio Oncology Therapeutics in the first quarter worth $392,000. Institutional investors and hedge funds own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

(Get Free Report)

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancers driven by RAS and related signaling pathways. The company’s research centers on disrupting molecular signals that help cancer cells grow and survive. Its development programs include drug candidates designed to target KRAS mutations and interactions between RAS and other cancer-related proteins. These investigational medicines are being studied for potential use in solid tumors; they are not approved treatments.

Further Reading

Analyst Recommendations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)

Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.